Skin And Skin Structure Infections (SSSI) Caused By Bacteria 2013
Albany, NY (PRWEB) December 14, 2013 -- Global Markets Directs, 'Skin And Skin Structure Infections (SSSI) Caused By Bacteria Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. Skin And Skin Structure Infections (SSSI) Caused By Bacteria Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.
To Read the Complete Report with TOC, Visit: http://www.marketresearchreports.biz/analysis-details/skin-and-skin-structure-infections-sssi-caused-by-bacteria-pipeline-review-h2-2013
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
• A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI) Caused By Bacteria.
• A review of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/180766
Reasons to Buy
• Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
To Buy The Copy of This Report, Visit: http://www.marketresearchreports.biz/analysis/180766
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Skin And Skin Structure Infections (SSSI) Caused By Bacteria 8
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Products under Development by Companies 16
Companies Involved in Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics Development 17
GlaxoSmithKline plc 17
Cubist Pharmaceuticals, Inc. 18
Paratek Pharmaceuticals, Inc. 19
Affinium Pharmaceuticals, Inc. 20
MerLion Pharmaceuticals Pte Ltd 21
Nabriva Therapeutics AG 22
Cempra Pharmaceuticals, Inc. 23
Tetraphase Pharmaceuticals Inc. 24
Durata Therapeutics Inc. 25
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
dalbavancin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GSK-1322322 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AFN-1252 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AFN-1252 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
omadacycline tosylate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BC-7013 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
delafloxacin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
oritavancin disphosphate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
fusidic acid - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
tedizolid phosphate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tedizolid phosphate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
avarofloxacin hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
eravacycline - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Bismith-Thiol Compound For Acute Wound Infection - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
AFN-1720 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Drug Profile Updates 61
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Dormant Products 88
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Product Development Milestones 89
Featured News & Press Releases 89
Oct 22, 2013: Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections 89
Oct 14, 2013: Cellceutix Drug Brilacidin May Be the Key Antibiotic on the Horizon for Serious Skin Infections; Plans to Start Phase 2b Study in January 2014 89
Oct 02, 2013: Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013 90
Sep 26, 2013: Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections 93
Sep 25, 2013: Dalbavancin Study Results to be Presented at IDWeek 2013 94
Sep 10, 2013: Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC 95
Sep 10, 2013: Phase 3 Data From The Medicines Company\'s Oritavancin Solo Trials Featured at ICAAC Conference 97
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 98
Jul 02, 2013: The Medicines Company Announces Positive Results for Solo II Trial of Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections 100
Jun 12, 2013: Trius Therapeutics Announces Publication Of Antibiotic Safety Study In Antimicrobial Agents And Chemotherapy 101
Latest Reports:
Intrathecal Pumps Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/intrathecal-pumps-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
Intrathecal pumps classified under intrathecal drug delivery system are used to deliver small amounts of drug directly to the patient’s spinal fluid for relieving chronic back or spinal pain. This small programmed battery powered pump is surgically implanted under the subcutaneous tissue of the abdomen and is connected to a catheter tunneled to the site of spinal entry. Such devices consist of a computerized pain pump, a catheter and a reservoir which needs to be refilled every 1 to 3 months. In this drug delivery system, a lower dose of medication is required since the drug is delivered directly at the site of action and thus bypasses the phase of circulation throughout the body.
Intrathecal pumps market is categorized on the basis of the following applications:
• Cancer Pain
• Neuropathic Pain
• Facial & Migraine Pain
• Musculoskeletal Pain
• Trauma
Globally, North America and western European countries dominates the intrathecal implant pumps market due to high prevalence of chronic or recurring pain in the general population, better reimbursement policies and increased awareness about healthcare and wellbeing in these regions. Emerging economies of Asia, Middle East and Latin America are predicted to incur the highest growth due to growing disease awareness and rising affordability in order to undertake such procedures.
Some of the key factors driving the growth of intrathecal pumps market are global growing elderly population and advances in technology. Increased incidences of cancer and diabetes, improved reimbursement policies and funding by government agencies, particularly in developing countries will further propel the intrathecal pumps market. However, high cost involved in implantation procedure of intrathecal pumps may pose a challenge to the growth of this market.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/toc/175282
Some of the major companies contributing to the intrathecal pumps market include Baxter International Inc., Boston Scientific Corporation, Codman and Shurtleff, Inc., Hospira, Inc., Kimberly-Clark Corporation, St. Jude Medical, Inc., Medtronic, Inc., Advanced Bionics LLC, Medasys, Inc., Flowonix Medical, Inc., Smiths Medical ASD, Inc. and Stryker Corporation.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
• North America
• Asia Pacific
• Europe
• Rest of the World
This report provides comprehensive analysis of
• Market growth drivers
• Factors limiting market growth
• Current market trends
• Market structure
• Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Fault Current Limiter/Controller Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/fault-current-limitercontroller-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
FCL is one of the emerging markets with a number of manufacturers offering prototypes for test and verification by the distributors mainly in U.K and the U.S. The concept, however, is appreciated and it is accepted that existing technologies do not fulfill the requirements and market needs. FCL’s have gained wide acceptance in North America and Europe owing to the unique safety features they offer to the power sources. The demand for commercial power has increased due to growing industrialization, chiefly in Asia-Pacific. Raising concerns among power suppliers to provide safe and secure transmission of electricity to the customers have spurred the market growth.
Human body is a good conductor of electricity. If any part of the body comes in contact with electrical supply, electricity flows in the body through the tissues which can cause extensive burns and can even stop the heart. The ability of FCL’s to control the risk of faults by limiting the power transmission through power systems; thereby adding to the safety of the customers is a major factor driving the market. Government of U.K awarded around USD 1 million to the Department of Energy and Climate Change for the development of next generation FCL’s. However, FCL’s are still in their emerging phase and the governments are likely to increase the use of FCL’s in the next three years providing opportunities for the market.
Rongxin Power Electronic Co. Ltd., Nexans and American Superconductors (AMSC), ABB Limited are some of the key participants in the FCL’s market. Recently, Nexans and AMSC introduced FCL’s for North American utilities to improve grid reliability and operations while reducing costs.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/toc/175283
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
• North America
• Asia Pacific
• Europe
• Rest of the World
This report provides comprehensive analysis of
• Market growth drivers
• Factors limiting market growth
• Current market trends
• Market structure
• Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Blog: http://mrrfocuseconomics.blogspot.com/
Michell Thoras, Market Research Reports, http://www.marketresearchreports.biz/, +1 (518) 618-1030, [email protected]
Share this article